Molecularly Targeted Therapy: Have the Floodgates Opened?
- 1 July 2004
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 9 (4) , 357-360
- https://doi.org/10.1634/theoncologist.9-4-357
Abstract
The Oncologist is a journal devoted to medical and practice issues for surgical, radiation, and medical oncologists.This publication has 15 references indexed in Scilit:
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Gleevec: Prototype or Outlier?Science's STKE, 2004
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2003
- PDGFRA Activating Mutations in Gastrointestinal Stromal TumorsScience, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Sceptical scientistsThe Lancet, 2001
- Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I studyThe Lancet, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemiaJournal of Clinical Investigation, 2000